(SOLV) Solventum - Ratings and Ratios
Medical Supplies, Dental Products, Software Solutions, Filtration
SOLV EPS (Earnings per Share)
SOLV Revenue
Description: SOLV Solventum
Solventum Corporation is a healthcare company that develops, manufactures, and commercializes a diverse portfolio of solutions across four key segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The companys product offerings cater to critical customer and patient needs, both domestically and internationally.
Breaking down the segments, Medsurg provides a range of medical solutions, including wound care, surgical supplies, and medical technologies. Dental Solutions offers orthodontic and dental products. Health Information Systems delivers software solutions for healthcare providers, focusing on documentation, billing, and data visualization. Purification and Filtration supplies technologies for purification and filtration across various industries. The companys diversified product portfolio and global reach position it for potential growth.
From a financial perspective, Solventum Corporation has a market capitalization of approximately $12.77 billion, indicating a significant presence in the healthcare equipment sector. With a forward P/E ratio of 13.30, the market anticipates earnings growth. The return on equity (RoE) stands at 12.35%, suggesting the company generates substantial returns for its shareholders. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth rate, gross margin ratio, and operating cash flow margin should be monitored.
Analyzing the companys operational efficiency, its essential to track metrics like inventory turnover, accounts receivable turnover, and days sales outstanding (DSO). A thorough examination of these KPIs will provide insights into Solventums ability to manage its working capital and respond to changing market conditions. Additionally, monitoring the companys research and development (R&D) expenses as a percentage of revenue can help assess its commitment to innovation and future growth.
To gain a more comprehensive understanding of Solventum Corporations position within the healthcare equipment industry, its crucial to compare its financial and operational performance to that of its peers. This analysis will help identify areas of strength and weakness, as well as potential opportunities for growth and improvement.
SOLV Stock Overview
| Market Cap in USD | 12,531m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2024-03-26 |
SOLV Stock Ratings
| Growth Rating | 17.3% |
| Fundamental | 46.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -0.69% |
| Analyst Rating | 3.25 of 5 |
SOLV Dividends
Currently no dividends paidSOLV Growth Ratios
| Growth Correlation 3m | -63.8% |
| Growth Correlation 12m | 38% |
| Growth Correlation 5y | 69.3% |
| CAGR 5y | -6.16% |
| CAGR/Max DD 5y | -0.15 |
| Sharpe Ratio 12m | -0.07 |
| Alpha | 10.99 |
| Beta | 0.511 |
| Volatility | 24.14% |
| Current Volume | 821.2k |
| Average Volume 20d | 879.3k |
| Stop Loss | 70.8 (-3.1%) |
| Signal | -0.09 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (380.0m TTM) > 0 and > 6% of Revenue (6% = 503.3m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -9.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.01% (prev 9.58%; Δ -2.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 586.0m > Net Income 380.0m (YES >=105%, WARN >=100%) |
| Net Debt (7.32b) to EBITDA (1.28b) ratio: 5.74 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (175.2m) change vs 12m ago 0.98% (target <= -2.0% for YES) |
| Gross Margin 54.52% (prev 55.61%; Δ -1.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.58% (prev 56.70%; Δ -0.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.76 (EBITDA TTM 1.28b / Interest Expense TTM 421.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.68
| (A) 0.04 = (Total Current Assets 3.21b - Total Current Liabilities 2.62b) / Total Assets 15.07b |
| (B) 0.03 = Retained Earnings (Balance) 468.0m / Total Assets 15.07b |
| (C) 0.05 = EBIT TTM 742.0m / Avg Total Assets 14.83b |
| (D) -0.01 = Book Value of Equity -161.0m / Total Liabilities 11.43b |
| Total Rating: 0.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 46.68
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield 0.65% = 0.33 |
| 3. FCF Margin 1.75% = 0.44 |
| 4. Debt/Equity 2.86 = -0.57 |
| 5. Debt/Ebitda 8.18 = -2.50 |
| 6. ROIC - WACC 0.56% = 0.70 |
| 7. RoE 11.64% = 0.97 |
| 8. Rev. Trend 75.73% = 3.79 |
| 9. Rev. CAGR 2.69% = 0.34 |
| 10. EPS Trend -72.18% = -1.80 |
| 11. EPS CAGR -38.35% = -2.50 |
What is the price of SOLV shares?
Over the past week, the price has changed by -0.63%, over one month by -0.63%, over three months by +0.66% and over the past year by +16.16%.
Is Solventum a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SOLV is around 67.64 USD . This means that SOLV is currently overvalued and has a potential downside of -7.46%.
Is SOLV a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 8
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the SOLV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 86.7 | 18.6% |
| Analysts Target Price | 82.2 | 12.4% |
| ValueRay Target Price | 72.8 | -0.4% |
Last update: 2025-08-21 02:50
SOLV Fundamental Data Overview
CCE Cash And Equivalents = 492.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 33.1514
P/E Forward = 13.0208
P/S = 1.4939
P/B = 3.4378
Beta = None
Revenue TTM = 8.39b USD
EBIT TTM = 742.0m USD
EBITDA TTM = 1.28b USD
Long Term Debt = 7.82b USD (from longTermDebt, last quarter)
Short Term Debt = 2.62b USD (from totalCurrentLiabilities, last quarter)
Debt = 10.44b USD (Calculated: Short Term 2.62b + Long Term 7.82b)
Net Debt = 7.32b USD (from netDebt column, last quarter)
Enterprise Value = 22.47b USD (12.53b + Debt 10.44b - CCE 492.0m)
Interest Coverage Ratio = 1.76 (Ebit TTM 742.0m / Interest Expense TTM 421.0m)
FCF Yield = 0.65% (FCF TTM 147.0m / Enterprise Value 22.47b)
FCF Margin = 1.75% (FCF TTM 147.0m / Revenue TTM 8.39b)
Net Margin = 4.53% (Net Income TTM 380.0m / Revenue TTM 8.39b)
Gross Margin = 54.52% ((Revenue TTM 8.39b - Cost of Revenue TTM 3.81b) / Revenue TTM)
Tobins Q-Ratio = -139.6 (set to none) (Enterprise Value 22.47b / Book Value Of Equity -161.0m)
Interest Expense / Debt = 0.99% (Interest Expense 103.0m / Debt 10.44b)
Taxrate = 20.99% (from yearly Income Tax Expense: 127.0m / 605.0m)
NOPAT = 586.2m (EBIT 742.0m * (1 - 20.99%))
Current Ratio = 1.22 (Total Current Assets 3.21b / Total Current Liabilities 2.62b)
Debt / Equity = 2.86 (Debt 10.44b / last Quarter total Stockholder Equity 3.65b)
Debt / EBITDA = 8.18 (Net Debt 7.32b / EBITDA 1.28b)
Debt / FCF = 70.99 (Debt 10.44b / FCF TTM 147.0m)
Total Stockholder Equity = 3.26b (last 4 quarters mean)
RoA = 2.52% (Net Income 380.0m, Total Assets 15.07b )
RoE = 11.64% (Net Income TTM 380.0m / Total Stockholder Equity 3.26b)
RoCE = 6.70% (Ebit 742.0m / (Equity 3.26b + L.T.Debt 7.82b))
RoIC = 5.22% (NOPAT 586.2m / Invested Capital 11.23b)
WACC = 4.66% (E(12.53b)/V(22.97b) * Re(7.90%)) + (D(10.44b)/V(22.97b) * Rd(0.99%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 94.90 | Cagr: 0.53%
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 74.68% ; FCFE base≈697.4m ; Y1≈561.2m ; Y5≈385.6m
Fair Price DCF = 41.24 (DCF Value 7.15b / Shares Outstanding 173.4m; 5y FCF grow -23.40% → 3.0% )
Revenue Correlation: 75.73 | Revenue CAGR: 2.69%
Rev Growth-of-Growth: -0.23
EPS Correlation: -72.18 | EPS CAGR: -38.35%
EPS Growth-of-Growth: -2.90
Additional Sources for SOLV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle